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Carbapenem-resistant Pseudomonas aeruginosa is one of the major concerns in clinical
settings impelling a great challenge to antimicrobial therapy for patients with infections
caused by the pathogen. While membrane permeability, together with derepression of
the intrinsic beta-lactamase gene, is the global prevailing mechanism of carbapenem
resistance in P. aeruginosa, the acquired genes for carbapenemases need special
attention because horizontal gene transfer through mobile genetic elements, such as
integrons, transposons, plasmids, and integrative and conjugative elements, could
accelerate the dissemination of the carbapenem-resistant P. aeruginosa. This review
aimed to illustrate epidemiologically the carbapenem resistance in P. aeruginosa,
including the resistance rates worldwide and the carbapenemase-encoding genes along
with the mobile genetic elements responsible for the horizontal dissemination of the
drug resistance determinants. Moreover, the modular mobile elements including the
carbapenemase-encoding gene, also known as the P. aeruginosa resistance islands,
are scrutinized mostly for their structures.
Keywords: carbapenem resistance, carbapenemase, molecular epidemiology, Pseudomonas aeruginosa, mobile
genetic elements, genomic islands
INTRODUCTION
Pseudomonas aeruginosa is a non-fermentative and aerobic Gram-negative bacillus that is one
of the leading causes of severe health care-associated infections targeting immunocompromised
patients (Rice, 2008). The bacterial species is an opportunistic pathogen not only for humans but
also for plants and animals. P. aeruginosa is metabolically versatile, and it has an enormous ability
for adaptation to different conditions with genome plasticity (Shen et al., 2006). There are diverse
opinions whether the pangenome of P. aeruginosa is still open or closed to acquire foreign genes
(Klockgether et al., 2011; Mosquera-Rendon et al., 2016). The accessory genome is often composed
of genes involved in virulence to human hosts and antimicrobial resistance, resulting in a high risk
of mortality and a high rate of multidrug resistance (Moradali et al., 2017). P. aeruginosa has a
median genome size value of 6.7 Mbp, a median number of 6,016 coding sequences, and 66.1% GC
on average (NCBI, 2020).
Although beta-lactams are one of the most commonly used antimicrobial drug classes
for P. aeruginosa infection, antipseudomonal beta-lactam drugs are limited because of the
species’ intrinsic resistance due to the interplay of chromosomal beta-lactamases (Livermore
and Yang, 1987), a low outer membrane permeability (Angus et al., 1982), and the
constitutive expression of efflux pump systems (Li et al., 1995). The beta-lactam regimens for
P. aeruginosa infection include antipseudomonal penicillins in combination with a beta-lactamase
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inhibitor, i.e., piperacillin–tazobactam and ticarcillin–clavulanic
acid; antipseudomonal cephalosporins alone or in combination
with beta-lactamase inhibitors, i.e., ceftazidime (with avibactam),
ceftolozane (with tazobactam), cefoperazone (with sulbactam),
and cefepime (Slack, 1981); and carbapenems, i.e., imipenem
and meropenem. Among those, carbapenems are the preferred
choice against multidrug-resistant P. aeruginosa. In recent
years, the rate of carbapenem resistance in P. aeruginosa has
increased worldwide and has become of great concern since
it significantly restricts the therapeutic options for patients
(El Solh and Alhajhusain, 2009). Carbapenem resistance in
P. aeruginosa is caused by chromosomal substitutions resulting in
membrane permeability alterations through porin loss and efflux
pump overexpression, together with intrinsic beta-lactamase
derepression, and the acquisition of the genes for carbapenemases
(Livermore, 1992; Masuda et al., 2000; Lister et al., 2009).
In this review, we summarized carbapenem resistance in
P. aeruginosa. The first half of this review outlines the worldwide
epidemiology and the second half discusses the mechanisms
of carbapenem resistance and the mobile genetic elements
responsible for the horizontal dissemination of resistance
determinants. All of the information in the review was collected
and analyzed from the National Database of Antibiotic Resistant
Organisms1 using the Reference Gene Catalog ver. 2020-09-22.22
for the carbapenemases and the Genome Database (last updated
on 22 September 2020)3 for the complete P. aeruginosa genomes.
CARBAPENEMS FOR
ANTIPSEUDOMONAL TREATMENT AND
RESISTANCE IN P. aeruginosa
Carbapenems for the Treatment of
Patients With P. aeruginosa Infection
Beta-lactams act by binding to and inactivating the penicillin-
binding proteins (PBPs), which have an essential role for
the completion of peptidoglycan biosynthesis through their
dual activity as a transglycosylase and transpeptidase. Among
the beta-lactams, carbapenems are the most effective against
Gram-positive and Gram-negative bacteria, presenting a broad
spectrum of antibacterial activity. Replacing the sulfur atom at
the C-1 position of the penicillin backbone by a carbon atom
(the red dot of the carbapenem backbone in the box in Figure 1)
allows exceptional stability against most enzymes inactivating
beta-lactams (Papp-Wallace et al., 2011).
The early carbapenem ertapenem has a bulky R3 moiety,
resulting in a weak affinity to the PBP3 of P. aeruginosa, and
consequently, the drug has little activity against P. aeruginosa
(Figure 1). Thus, the late carbapenems imipenem and
meropenem are actively used for the treatment of infections (Luyt
et al., 2014). Among the three antipseudomonal carbapenems,




lowest minimum inhibitory concentrations (MICs) for wild
P. aeruginosa strains (Figure 1). Meropenem presents good
affinity to the active site of PBP3 (Figure 2). The recently
developed combinations of beta-lactam/beta-lactamase inhibitor,
such as aztreonam–avibactam, meropenem–vaborbactam,
and imipenem–relebactam, have a limited efficacy against
the metallo-beta-lactamase (MBL)-producing carbapenem-
resistant P. aeruginosa (Karlowsky et al., 2017, 2020; Lob
et al., 2020). However, the siderophore cephalosporin
cefiderocol (Delgado-Valverde et al., 2020) is effective against
all the carbapenemase-producing P. aeruginosa, including
the MBL producers.
Carbapenem Resistance in P. aeruginosa
The rate of carbapenem resistance in P. aeruginosa varies
worldwide (Figure 3). According to the Antimicrobial Testing
Leadership and Surveillance program by Pfizer in 2018 (last
updated on September 14, 2020) (Pfizer, 2020), the rate of
resistant clinical strains (-R) of P. aeruginosa by continent was
the lowest in Oceania (imipenem-R in 7.1% and meropenem-
R in 5.1% of 99 isolates from Australia), and the highest was
in the Middle East (imipenem-R in 27.9% and meropenem-R
in 19.5% of 226 isolates from four participating countries). In
descending order, the median resistance rates were 30.7% in
South America (the lowest imipenem-R and meropenem-R both
in 12.5% of 24 isolates from the Dominican Republic and the
highest imipenem-R in 49.3% and meropenem-R in 75.3% in 75
isolates from Chile, among nine participating countries), 28.0%
in Europe (the lowest 0.0% of 19 isolates from Finland and
the highest imipenem-R in 48.5% and meropenem-R in 44.8%
of 194 isolates from Russia, among 24 participating countries),
24.4% in North America (imipenem-R in 21.4% and meropenem-
R in 18.3% of 197 isolates from Canada and imipenem-R in
27.4% and meropenem-R in 15.5% of 588 isolates from the
United States), 22.8% in Africa (the lowest imipenem-R in 13.2%
and meropenem-R in 15.8% of 38 isolates from Nigeria and the
highest imipenem-R in 21.4% and meropenem-R in 19.4% of 98
isolates from South Africa, among three participating countries),
and 18.1% in Asia (the lowest imipenem-R and meropenem-R
both in 8.0% of 75 isolates from Japan and the highest imipenem-
R in 33.2% and meropenem-R in 25.1% of 386 isolates from
China, among 10 participating countries).
Epidemic High-Risk P. aeruginosa
Clones
The current P. aeruginosa high-risk clones, which meet both
requirements of global dominance and association with the
multidrug-resistant phenotype, include 10 P. aeruginosa lineages
belonging to ST111, ST175, ST233, ST235, ST244, ST277, ST298
(CC445), ST308, ST357, and ST654 (Del Barrio-Tofino et al.,
2020). The multidrug-resistant P. aeruginosa ST111, ST175,
and ST235 have been identified to carry genomic islands
(Roy Chowdhury et al., 2017). While all the 10 high-risk
clones are relevant to MBL production, ST235 and ST111
are by far the most worrisome carbapenemase producers,
associated not only with class B but also with class A and
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FIGURE 1 | Carbapenem drugs. The backbone of carbapenems is in a box. The C-1 position replaced from the sulfur atom in the penicillin backbone is indicated
with a red dot. The important R1 and R3 positions are indicated with red letters. Ertapenem with a bulky R3 residue, which does not have enough affinity to be active
against Pseudomonas aeruginosa, is presented with the other three carbapenems having antipseudomonal activity.
D carbapenemases. The widespread P. aeruginosa ST235 clone
is often associated with poor clinical outcomes due to its
multidrug resistance and virulence factors, representatively
the cytotoxin ExoU causing necrotic cell death (Sato et al.,
2003; Roy Chowdhury et al., 2016; Yoon et al., 2019).
The second dominant P. aeruginosa clone is ST111, which
has been identified in all six continents except Oceania
(Del Barrio-Tofino et al., 2020).
MECHANISMS OF RESISTANCE TO
CARBAPENEMS IN P. aeruginosa
Chromosomal Mutation-Derived
Carbapenem Resistance
Pseudomonas aeruginosa can acquire resistance to carbapenems
by chromosomal mutations (Lister et al., 2009). Loss of
the outer membrane protein OprD, which is a channel for
imipenem penetration (Margaret et al., 1989), is associated
with a reduced susceptibility to carbapenems, mostly imipenem
(Farra et al., 2008). Early reports have underlined OprD
deficiency as the predominant mechanism of carbapenem
resistance in P. aeruginosa (Margaret et al., 1989; Kohler et al.,
1999). The overexpression of efflux pump systems, such as
MexAB-OprM, by mutation at the regulatory region contributes
directly to the resistance to meropenem (Kohler et al., 1999;
Masuda et al., 2000) and mutational derepression of the
chromosomal cephalosporinase AmpC, especially the extended-
spectrum cephalosporinases (Rodriguez-Martinez et al., 2009a),
and plays a part in carbapenem resistance (Quale et al.,
2006; Rodriguez-Martinez et al., 2009b). The combination
of porin loss, efflux pump overexpression, and chromosomal
cephalosporinase derepression is able to confer high-level
resistance to carbapenems, and P. aeruginosa could have elevated
imipenem and meropenem MICs up to 256 and 128 mg/L,
respectively (Chalhoub et al., 2016).
Enzymatic Mechanisms of Carbapenem
Resistance
Before 1990, the only known mechanism of carbapenem
resistance was mutations occurring in the chromosome.
Following the first identification of an MBL-producing
P. aeruginosa clinical strain (Watanabe et al., 1991; Minami
et al., 1996), a retrospective screening of P. aeruginosa identified
the blaIMP−1 gene in 1992 in Japan (Senda et al., 1996a).
Subsequent outbreaks due to the transferable drug resistance
conferred by the gene were reported (Senda et al., 1996b). The
blaVIM−1 gene encoding the Verona integron-encoded MBL
(VIM) subtype 1 in P. aeruginosa clinical strain was identified
in 1997 in Italy in a P. aeruginosa clinical isolate (Lauretti
et al., 1999). And the carbapenem-resistant P. aeruginosa spread
rapidly through the contribution of mobile genetic elements and
high-risk clones. Thus far, class A, B, and D carbapenemases have
been identified in P. aeruginosa, and the class B MBL enzyme is
the most prevalent (Queenan and Bush, 2007).
Class A Beta-Lactamases
The class A beta-lactamases include serine at amino acid (aa)
70 at the active site and the general base Glu-166 is involved in
the catalytic process, which makes a difference from the other
serine beta-lactamases of classes C and D (Matagne et al., 1999).
In P. aeruginosa, the Klebsiella pneumoniae carbapenemase
(KPC) and the Guiana extended-spectrum beta-lactamase (GES)
belonging to the class A beta-lactamases with carbapenemase
activity have been identified. The class A carbapenemases
actively hydrolyze carbapenems and are partially inhibited by
clavulanic acid.
Klebsiella pneumoniae carbapenemase was first discovered
in a K. pneumoniae clinical isolate from North Carolina,
United States, in 1996, presenting a specific pattern of resistance
to penicillins, extended-spectrum cephalosporins, and aztreonam
(Yigit et al., 2001). The first KPC-producing P. aeruginosa
isolate was identified in Colombia in Villegas et al. (2007), and
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FIGURE 2 | A stereoview of PBP3 of Pseudomonas aeruginosa complexed with meropenem (PDB ID, 3PBR) and the interaction of the meropenem in the ligand
pocket of PBP3 (Han et al., 2010). The structure of PBP3 is colored by secondary structure, and the meropenem is in a ball-and-stick presentation. The molecular
surface of PBP3 in the binding pocket is presented with the interacting amino acid residue complex with meropenem in a ball-and-stick presentation.
subsequent reports of the pathogen followed all over the world,
including America (Akpaka et al., 2009; Poirel et al., 2010;
Robledo et al., 2011; Jacome et al., 2012; Ramirez et al., 2013;
Kazmierczak et al., 2016a; Walkty et al., 2019), Asia (Ge et al.,
2011; Paul et al., 2015; Falahat et al., 2016; Hagemann et al., 2018),
and Europe (Figure 4).
Among the GES-type class A beta-lactamases, only the
variants with alterations at aa 170 from glycine to asparagine or
serine with a polar uncharged side chain are able to hydrolyze
carbapenems (Frase et al., 2009). Among the 43 GES variants,
subtypes 4–6, 14–16, 18, 20, 21, 24, 25, 27–30, 33, 34, 36,
37, 39, 40–42, and 43 with serine at aa 170 and variants 2
and 13 with asparagine at aa 170 have carbapenem-hydrolyzing
activity. Of note is that variant 22, having a substitution to
leucine with a hydrophobic side chain at aa 170, does not confer
resistance to carbapenems (Castanheira et al., 2014a). GES-type
carbapenemase-producing P. aeruginosa has been identified in
North and South America [Canada (McCracken et al., 2019),
Mexico (Treepong et al., 2018), and Brazil (Polotto et al.,
2012)], in Europe [including Belgium (Bebrone et al., 2013),
Turkey (Malkocoglu et al., 2017), Spain (Viedma et al., 2009;
Treepong et al., 2018), and Russia (Treepong et al., 2018)],
in Africa [South Africa (Poirel et al., 2001); in the Middle
East of Lebanon (Yaghi et al., 2019)], in Asia [including Japan
(Hishinuma et al., 2018), India (Maurya et al., 2014), China
(Wang et al., 2006a), and South Korea (Hong et al., 2016;
Jabalameli et al., 2018)], and in Oceania [Australia (Sherry et al.,
2018)] (Figure 4).
The carbapenem-hydrolyzing class A beta-lactamase
producers mostly belong to ST235, ST111, ST357, and ST463.
The KPC-, and GES-5-producing P. aeruginosa clones have
been identified in Europe [Spain (Viedma et al., 2009), Italy
(Giani et al., 2018), Lithuania (Mikucionyte et al., 2016), Turkey,
Germany (Castanheira et al., 2014b), Belarus, and Russia
(Edelstein et al., 2013)] and in Asian countries [Kazakhstan
(Edelstein et al., 2013), Thailand (Khuntayaporn et al., 2019),
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FIGURE 3 | Rates of imipenem resistance in Pseudomonas aeruginosa worldwide in 2018. All the data were extracted from the Antimicrobial Testing Leadership and
Surveillance run by Pfizer (last updated on October 30, 2019) (Pfizer, 2020), except for the data from South Korea (unpublished data). The actual resistance rates are
indicated per continent as follows: Africa [three participating countries: Morocco (N = 79, 22.8%), Nigeria (N = 38, 13.2%), South Africa (N = 98, 21.4%)]; Asia [10
participating countries: China (N = 386, 33.2%), Hong Kong (N = 25, 24%), India (N = 125, 29.6%), Japan (N = 75, 8%), Malaysia (N = 55, 21.8%), Philippines
(N = 74, 18.9%), Singapore (N = 25, 16%), South Korea (N = 127, 18.1%), Taiwan (N = 99, 9.1%), and Thailand (N = 75, 16%)]; Europe [24 participating countries:
Belgium (N = 150, 21.3%), Croatia (N = 78, 35.9%), Czech Republic (N = 102, 29.4%), Denmark (N = 25, 8%), Finland (N = 19, 0%), France (N = 248, 20.2%),
Germany (N = 248, 27.4%), Greece (N = 75, 30.7%), Hungary (N = 100, 42%), Ireland (N = 64, 18.8%), Italy (N = 242, 28.5%), Latvia (N = 24, 33.3%), Lithuania
(N = 50, 22%), Poland (N = 101, 39.6%), Portugal (N = 99, 32.3%), Romania (N = 99, 45.5%), Russia (N = 194, 48.5%), Netherlands (N = 40, 17.5%), Spain
(N = 273, 19.4%), Sweden (N = 25, 8%), Switzerland (N = 50, 10%), Turkey (N = 60, 43.3%), Ukraine (N = 53, 54.7%), and United Kingdom (N = 158, 19.6%)]; Mid
and South America [10 participating countries: Brazil (N = 116, 16.4%), Chile (N = 75, 49.3%), Colombia (N = 124, 30.7%), Costa Rica (N = 22, 13.6%), Dominican
Republic (N = 24, 12.5%), Guatemala (N = 55, 16.4%), Mexico (N = 146, 42.5%), Panama (N = 32, 37.5%), and Venezuela (N = 64, 45.3%)]; North America [two
participating countries: Canada (N = 197, 27.4%) and the United States (N = 588, 21.4%),]; Middle East [four participating countries: Israel (N = 100, 12%), Jordan
(N = 24, 29.2%), Kuwait (N = 76, 44.7%), and Saudi Arabia (N = 26, 38.5%)]; and Oceania [a single participating country: Australia (N = 99, 7.1%)].
China (Hu et al., 2015), and South Korea (Hong et al.,
2016)] (Figure 5).
Class B Beta-Lactamases
The class B beta-lactamases are also known as “metallo-” beta-
lactamases because they need divalent cations, usually Zn2+
ions, as a metal cofactor to hydrolyze beta-lactams. Although
class B beta-lactamases are subclassified as B1, B2, and B3
based on structural and functional points (Frere et al., 2005),
we will discuss subclass B1, the only dominant subclass in
P. aeruginosa. The B1 subclass contains the largest number of
clinically relevant acquired MBLs, not only in P. aeruginosa
but also in Enterobacterales and other Gram-negative non-
fermenters. MBLs bind two Zn2+ atoms for optimal hydrolysis.
Zn2+ ion ligands bind at 3H (His–His–His) and DCH (Asp–
Cys–His) sites, and the binding of di-Zn2+ plays a critical role
in hydrolyzing beta-lactam substrates (Frere et al., 2005; Moran-
Barrio et al., 2016). Consequently, the carbapenemase activity
of MBLs is diminished in the presence of a chelator of Zn2+
and other divalent cations, i.e., ethylenediaminetetraacetic acid
(EDTA). The substrate profile of the MBLs includes penicillins,
cephalosporins, and carbapenems, but excludes monobactams.
The acquired MBL genes, located mostly within a class 1 integron
as gene cassettes, have been found in various bacterial species,
including P. aeruginosa.
Metallo-beta-lactamase are the most prevalent type of
carbapenemases produced by P. aeruginosa clinical isolates.
VIMs are the most disseminated, followed by imipenemases
(IMPs). New Delhi MBLs (NDMs) have also been identified.
Regional dissemination of P. aeruginosa clinical strains
producing Australian imipenemase (AIM), Central Alberta
MBL (CAM), Dutch imipenemase (DIM), Florence imipenemase
(FIM), German imipenemase (GIM), Hamburg MBL (HMB),
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FIGURE 4 | Worldwide identification of the carbapenemase-producing Pseudomonas aeruginosa. Reports of class A [Klebsiella pneumoniae carbapenemase (KPC)
and Guiana extended-spectrum beta-lactamase (GES) with amino acid alteration at aa 170], class B [Verona integron-encoded MBL (VIM), imipenemase (IMP), New
Delhi MBL (NDM), and others], and class D (OXA) carbapenemases are indicated in a geographic map. The references used for the map drawing are indicated in the
main text.
São Paulo MBL (SPM), and Seoul imipenemase (SIM)
was also reported.
A VIM-1-producing P. aeruginosa strain was first isolated
in Verona, Italy, in Lauretti et al. (1999). Together with
subtype VIM-2 (Poirel et al., 2000), the first two VIM enzymes
were originally found in P. aeruginosa as gene cassettes
of class 1 integrons. Notably, VIM-2 has a 10-fold more
efficient hydrolyzing activity to both imipenem and meropenem
compared to VIM-1 (Docquier et al., 2003), and in most of the
countries, VIM-2 is the dominant carbapenemase produced by
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FIGURE 5 | Epidemic carbapenemase-producing high-risk Pseudomonas aeruginosa clones identified worldwide. Regional dissemination of specific P. aeruginosa
clones identified through multilocus sequence typing (MLST) is indicated in color on a geographic map, and the carbapenemases produced are indicated at the
region. The number of countries with reports of the P. aeruginosa clone are indicated in the figure legends. References are indicated in the main text.
P. aeruginosa (Kazmierczak et al., 2016b). Thus far, a total of 66
variants of VIM have been identified, and subtype 2-producing
P. aeruginosa has been extensively spread, with a few regional
exceptions by specific outbreaks. VIM-producing P. aeruginosa
clinical strains have been identified in almost all countries
reporting surveillance data in six continents: in Europe (Poirel
et al., 2000; Pournaras et al., 2002; Bahar et al., 2004; Deplano
et al., 2007; Juan et al., 2008; Schneider et al., 2008; Siarkou
et al., 2009; Bosnjak et al., 2010; Samuelsen et al., 2010; Mazzariol
et al., 2011; Edelstein et al., 2013; Dortet et al., 2015; Kazmierczak
et al., 2016b), in Asia (Wang et al., 2006b; Khosravi and Mihani,
2008; Nho et al., 2008; Al-Agamy et al., 2009; Castanheira et al.,
2009; Azim et al., 2010; Khosravi et al., 2010; Koh et al., 2010;
Mano et al., 2015; Kazmierczak et al., 2016b; Tada et al., 2017,
2019; Tohya et al., 2019; Yaghi et al., 2019), in North (Toleman
et al., 2004; Pitout et al., 2007) and South America (Crespo
et al., 2004; Pasteran et al., 2005; Kazmierczak et al., 2016a; Rios
et al., 2018; Pacheco et al., 2019), in Africa (Pitout et al., 2008;
Ktari et al., 2011; Jeannot et al., 2013; Moyo et al., 2015; Kateete
et al., 2016; Adam and Elhag, 2018), and in Oceania (Tai et al.,
2015; Figure 4). P. aeruginosa ST111 mostly produces VIM-2 and
has been identified in European countries [the Czech Republic
(Papagiannitsis et al., 2017), Portugal (Botelho et al., 2018), Italy
(Giani et al., 2018), Greece, and Belgium (Castanheira et al.,
2014b)] and in Latin American countries [Colombia (Correa
et al., 2015)]. Less frequently, VIM-producing P. aeruginosa
ST244 was identified in China (Chen et al., 2014; Feng et al.,
2017), Brazil (de Oliveira Santos et al., 2019), and Africa (Cholley
et al., 2014); VIM-producing P. aeruginosa ST175 was identified
in Europe [Spain and Germany (Elias et al., 2010; Garcia-Castillo
et al., 2011; Viedma et al., 2012; Giani et al., 2018)].
After the first IMP enzyme found in Japan in Watanabe et al.
(1991), subsequent interspecies spread of the blaIMP gene to
Enterobacterales and Acinetobacter baumannii was reported in
Japan and Europe, respectively (Arakawa et al., 1995). Currently,
up to 79 variants of IMP have been identified, and varied subtypes
have been identified with regional inconsistency. The global
prevalent subtype is IMP-1, with a few exceptions of IMP-9 in
China (Xiong et al., 2006) and IMP-6 in South Korea (Ryoo
et al., 2009). Notably, IMP-6 has better hydrolyzing activity to
meropenem than to imipenem compared to the other subtypes
of IMP enzymes (Yano et al., 2001). IMP is the second most
common carbapenemase produced by P. aeruginosa regardless of
whether the strain was isolated in Europe (Hrabak et al., 2009,
2011; Samuelsen et al., 2010), in Asia (Xiong et al., 2006; Kouda
et al., 2007; Nho et al., 2008; Ryoo et al., 2009; Azim et al., 2010;
Khosravi et al., 2010; Koh et al., 2010; Tada et al., 2019; Yaghi
et al., 2019), in North (Gibb et al., 2002; Hanson et al., 2006),
and South America (Garza-Ramos et al., 2008; Kazmierczak et al.,
2016b), in Africa (Kateete et al., 2016; Adam and Elhag, 2018),
and in Oceania (McCarthy et al., 2017; Figure 4). P. aeruginosa
ST357 mostly produces IMP. The clone was spread in Europe
(Hrabak et al., 2011; Papagiannitsis et al., 2017) and Asia (Kouda
et al., 2009; Fan et al., 2016). IMP-producing P. aeruginosa ST621
was identified in Europe [Italy (Giani et al., 2018) and France
(Fournier et al., 2012)] (Figure 5).
The NDM enzyme was first identified in 2008 in
K. pneumoniae isolated from a Swedish patient with a history
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of travel to India (Yong et al., 2009). Shortly after, the NDM
producers became endemic in South Asian countries located in
the Indian subcontinent, such as India, Pakistan, and Bangladesh
(Kumarasamy et al., 2010; Dortet et al., 2014). The first report
of NDM-1-producing P. aeruginosa was in Serbia in Jovcic
et al. (2011), and subsequent dissemination was observed in
the Balkans (Jovcic et al., 2013; Kulkova et al., 2015). NDM-
producing P. aeruginosa has been identified mostly in Asia
(Khajuria et al., 2013; Paul et al., 2015; Tada et al., 2017, 2019;
Honda et al., 2019; Tohya et al., 2019), in Europe (Jovcic et al.,
2011; Carattoli et al., 2013; Janvier et al., 2013; Kulkova et al.,
2015; Urbanowicz et al., 2019), and in Africa (Manenzhe et al.,
2015; Kateete et al., 2016; Adam and Elhag, 2018). And, as a
sporadic emergence, it was also identified in North America
(Mataseje et al., 2016; Figure 4). Among a total of 27 variants of
NDM that have been identified, NDM-1 seems to be the most
prevalent subtype.
Being different from the intercontinental dissemination of
VIM-, IMP-, and NDM-producing P. aeruginosa, other MBL-
producing P. aeruginosa outbreaks or regional spreading have
occurred, except for SPM-producing P. aeruginosa. SPM-
producing P. aeruginosa was first identified in São Paulo, Brazil
(Toleman et al., 2002), and the clone belonged to ST277 (Chaves
et al., 2017; de Oliveira Santos et al., 2019). The SPM producer
was subsequently identified in Switzerland (Salabi et al., 2010),
the United Kingdom (Salabi et al., 2010), India (Azim et al.,
2010), China (Cai et al., 2016), and Uganda (Kateete et al.,
2016; Figure 4). DIM-producing P. aeruginosa clinical strains
were regionally disseminated mostly in Asia (Tada et al., 2017,
2019) and Europe (Urbanowicz et al., 2019). GIM-producing
P. aeruginosa was identified in Germany (Castanheira et al.,
2004; Wendel et al., 2015) and India (Azim et al., 2010).
SIM-producing P. aeruginosa was identified in China (Sun
et al., 2016). HMB-producing P. aeruginosa was identified
both in Hamburg, Germany (Pfennigwerth et al., 2017), and
in the United States (Walters et al., 2019). CAM-producing
P. aeruginosa was identified in Canada (Boyd et al., 2019), and no
more dissemination was observed. The AIM and FIM producers
were restricted in Australia (Yong et al., 2012) and Italy (Pollini
et al., 2013), respectively (Figure 4).
Class D Beta-Lactamases
Class D beta-lactamases belong to the superfamily of serine beta-
lactamases with a unique carboxylated Lys-73 responsible for
the beta-lactam hydrolysis activity (Golemi et al., 2001). The
carbapenem-hydrolyzing class D beta-lactamases (CHDLs) were
first described in A. baumannii and published by Paton et al.
(1993). CHDLs are serine beta-lactamases with a relatively weak
activity against carbapenems and are poorly inhibited by EDTA
or clavulanic acid. Among a total of 12 groups of CHDLs, three
groups—OXA-40-like, OXA-48-like, and OXA-198-like—have
been identified in P. aeruginosa.
OXA-type carbapenemases are rarely identified in
P. aeruginosa, and the emergence of the following strains
has been reported: OXA-40-producing P. aeruginosa in Spain
(Sevillano et al., 2009), OXA-48-producing P. aeruginosa in India
(Borah et al., 2016), OXA-181-producing P. aeruginosa in the
United Kingdom (Findlay et al., 2017), and OXA-198-producing




The acquired genes encoding carbapenemases are associated with
a plethora of mobile genetic elements, such as plasmids, gene
cassettes of integrons, transposons, and genomic islands (Kung
et al., 2010). Mobile genetic elements have the ability to move
from genome to genome by transformation, conjugation, and
transduction, presenting intracellular and intercellular mobility




In general, the plasmids carrying the carbapenemase-encoding
genes in P. aeruginosa belong to the distinct incompatibility
groups from those in Enterobacterales. Among the 13 known
incompatibility types of IncP, IncP-2-type plasmids are classic
types frequently identified in P. aeruginosa (Korfhagen et al.,
1976). Among the 207 complete genomes of P. aeruginosa of
the Genome Database (NCBI, 2020), five genomes include a
plasmid carrying one or two carbapenemase-encoding genes; two
of the five plasmids are of the IncP-2 incompatibility type, while
the other three are untypable: two blaKPC−2 genes are harbored
by untypable plasmids, which are almost the same (identical
nucleotide sequences, except for a 1-bp gap difference between
the 57,053- and 57,052-bp plasmids), one blaVIM−1 is harbored
by an untypable plasmid, one IncP-2 plasmid harbors blaIMP−45,
and one IncP-2 plasmid harbors both the blaVIM−1 and the
blaIMP−45 genes.
Among the plasmids in P. aeruginosa having an incomplete
genome, the 31,529- and 38,939-bp IncP-6 plasmids carrying
the blaKPC−2 gene have been identified in Colombia and China,
respectively (Naas et al., 2013; Dai et al., 2016), and the
7,995-bp IncU plasmid including the blaKPC−2 gene has been
identified in Colombia (Naas et al., 2013). An untypable 3,652-
bp plasmid harboring the blaKPC−2 gene was identified in Brazil
(Galetti et al., 2016).
Recently, a Pseudomonas plasmid lineage carrying the MBL
genes has been reported (Di Pilato et al., 2019). A retrospective
analysis revealed that the plasmid lineage has been identified
since the 1990s, mostly in Europe. While the plasmid does
not belong to a recognized plasmid type, the type 4 secretion
system components classified the plasmids as MOBF11 or MPFT
plasmid families. The MBL genes in the plasmid were identified as
gene cassettes of the class 1 integron In70 (Di Pilato et al., 2019).
Carbapenemase-Encoding
Gene-Associated Transposable Units
The carbapenemase-encoding genes are frequently included in
transposable elements, which are often associated with the
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FIGURE 6 | Transposable units identified in Pseudomonas aeruginosa carrying the carbapenemase-encoding genes. The red arrow indicates the genes for
antimicrobial resistance, and those with yellow letters inside indicate the genes for carbapenemase. Yellow arrows depict insertion sequences, and those in orange
indicate transposase/resolvase.
insertion sequences with a common region (ISCRs) being
responsible for the rapid transmission of bacterial multidrug
resistance (Figure 6; Toleman et al., 2006). Typically, the
ISCR element lacks flanking inverted repeats (IRs) and the
integration does not produce direct repeat (DR) sequences
(Diaz-Aroca et al., 1987). Rolling circle has been suggested
for the transmission mechanism of ISCRs (Figure 7), and the
transposition method allows a polarized transfer of the ISCR
elements to mobilize adjacent DNA sequences in varied sizes
(del Pilar Garcillan-Barcia et al., 2001).
The blaCAM and blaFIM genes were identified in transposable
elements associated with ISCR14 and ISCR19, respectively,
located downstream from the gene. The blaSPM gene was
identified in P. aeruginosa accompanied with the chaperone
groEL gene and flanked by a pair of ISCR4 elements. The
blaAIM gene was identified in a transposable element associated
with the upstream ISCR15. The blaHMB−1 gene was in a
transposable unit, namely, Tn6345 (Supplementary Table 1;
Pfennigwerth et al., 2017), flanked by IS1595 upstream and
ISCR27-like downstream (Toleman et al., 2006). For the
blaNDM gene, the composite transposon Tn125 flanked by a
pair of ISAba125 copies at both ends has been identified in
A. baumannii (Bontron et al., 2016). The blaNDM−1 gene-
associated transposable element is composed of a truncated
Tn125. ISCR is located upstream from the 1ISAba1, and
downstream of the blaNDM−1 gene, the ble gene for bleomycin
resistance and the trpF gene for phosphoribosylanthranilate
isomerase are followed (Sole et al., 2011).
The Tn4401 carrying the blaKPC gene has been found in
diverse bacterial hosts, including P. aeruginosa (Cuzon et al.,
2011; Figure 6). Tn4401 is a 10-kb transposon composed
of genes encoding a transposase and a resolvase, and the
blaKPC gene together with two insertion sequences (ISs),
ISKpn6 and ISKpn7 (Figure 6), and transposition of Tn4401
occurs through the mechanism of copy-and-paste replicative
transposition (Figure 7; Grindley, 1983). Tn4401 includes nine
isoforms from a to I differing in the sequences upstream
of the blaKPC gene (Naas et al., 2012; Bryant et al., 2013;
Cheruvanky et al., 2017; Araujo et al., 2018; Schweizer et al.,
2019). While both Tn4401a and Tn4401b are prevalent in
Enterobacterales (Stoesser et al., 2017; Yoon et al., 2018),
Tn4401b is the only isotype identified in P. aeruginosa. Seven
Tn4401 elements were found through the restricted BLAST
against the species P. aeruginosa, and all were Tn4401b:
two Tn4401b copies in a chromosome (GenBank accession
CP029605) and each Tn4401b copy in five plasmids (GenBank
accessions MN082782.1, CP027168.1, CP029092.1, KC609323.1,
and EU176013.1).
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FIGURE 7 | Mechanisms of replicative transposition of the transposons. (A) Insertion sequence with a common region (ISCR)-mediated rolling circle replicative
transposition is involved in rolling circle replication. ISCR elements lack terminal inverted repeats, and a single copy of the element is able to transpose adjacent DNA
sequences (Toleman et al., 2006). (B) A Tn3-mediated copy-and-paste replicative transposition requires both a transposase and a resolvase. The transposon is
replicated, joining the donor and the recipient in a cointegrate, which is resolved to give the donor and the recipient of the transposon (Grindley, 1983).
Class 1 Integrons Carrying
Carbapenemase-Encoding Gene
Cassettes
Integrons are assembly platforms comprising an intI gene for
a site-specific tyrosine recombinase, an attI for a primary
recombination site, the promoter Pc for transcription, and an
assemblage of passenger genes composing a gene cassette array
(Figure 8; Collis et al., 1993). The IntI integrase recognizes the
attC site of the gene cassette and the promoterless gene cassette is
inserted as a linear form in the integron (Figure 8; Collis and Hall,
1992). In addition to the catalysis of attC × attC, the integrase
catalyzes attI × attC, leading to the gene cassette integration
into the attI site. A successive integration of the gene cassettes
occurs downstream of the resident Pc promoter (Hall and Collis,
1995). The expression of the gene cassette is dependent on the
sole promoter and the level of gene expression depends on the
distance from the sole promoter Pc (Coyne et al., 2010). By
nature, the first few cassettes are expressed and the rest of the
array exists as a reservoir of standing genetic variation (Cambray
et al., 2010). Rearrangement of the order of gene cassettes affects
the resistance phenotype of the bacterial host (Hall and Collis,
1995; Rowe-Magnus et al., 2002).
Carbapenemase-Encoding Gene Cassettes
The class A carbapenemase-encoding gene blaGES, the MBL genes
blaVIM, blaIMP, and blaGIM−1, and the class D gene blaOXA−198
were identified as a gene cassette composing a class 1 integron.
In the integron database INTEGRALL (4last updated on 10
December 2020) (Moura et al., 2009), a total of 812 class 1
integrons of 282 different gene cassette arrays were identified for
the organism P. aeruginosa. Among them, 191 class 1 integrons of
148 different arrays carried one or two carbapenemase-encoding
gene cassettes (Supplementary Table 2). The most prevalent
blaVIM genes were identified as gene cassettes in 98 arrays of the
130 class 1 integrons. Among them, 13 carried only the blaVIM
4http://integrall.bio.ua.pt/
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FIGURE 8 | Organization of the integron and the process of capturing and
exchanging the gene cassettes. The open arrow indicates the open reading
frame and is colored based on its function: the antimicrobial resistance gene is
in red or in magenta, the attC gene is in green, and the intI1 gene is in orange.
The open box indicates the attI locus. The integron is organized as a
functional platform including the intI1 gene and the attI locus and a cassette
array assembled through the acquisition of gene cassettes structured with an
open reading frame and an attC locus. Expression of the gene cassettes is
dependent on the common promoter, Pc, and the level of expression
depends on the distance from the Pc. The IntI1 integrase binds to the attC
locus of the excised gene cassette to help circularize the cassette (Collis et al.,
1993; Hall and Collis, 1995).
cassette; the others harbored additional gene cassettes encoding
aminoglycoside-modifying enzymes, mostly the aacA genes and
less frequently the aadA or aadB genes. All but five carried the
blaVIM gene cassette in the first position of the array (62.3%) or
in the second position of the array (33.1%).
The second most dominant blaIMP cassettes were identified in
50 class 1 integrons of 40 different arrays, and 14 of the integrons
harbored a single gene cassette. All but two harbored the blaIMP
gene cassette in the first of the array (70.0%) or in the second
of the array (22.9%). Less frequently, the blaGIM−1 gene cassette
was identified in six class 1 integrons of five different arrays all
in the first of the array, and three blaGES−5 cassette-associated
and one of each of the blaGES−8, blaGES−9, and blaGES−15 cassette-
associated class 1 integrons were identified.
Mobilized Class 1 Integrons
Basically, class 1 integrons are immobile per se, and a set of
functional transposition modules is needed for transposition
(Martinez et al., 2012). The Tn402 family transposon Tn5090
is a good example of a functional transposon giving mobility
to a class 1 integron (Figure 9; Radstrom et al., 1994). The
Tn402 family transposon is a Mu-related transposon that has
been identified in the broad-host IncP plasmid R751 conferring
trimethoprim resistance (Jobanputra and Datta, 1974; Shapiro
and Sporn, 1977). The transposon family has two modules:
a transposition module composed of the transposase TniA,
the ATP-binding protein TniB, the transposition auxiliary
protein TniQ-resolution site res, the serine resolvase TniC,
and a class 1 integron carrying antimicrobial resistance gene
cassettes. Transposition of the Tn402 family transposon involves
a TniABQ-dependent cointegrate formation and a site-specific
serine resolvase-dependent resolution (Radstrom et al., 1994).
The transposon has 25-bp inverted repeats, and the integration
generates 5-bp DRs. The transposon targets the res site of
Tn21 subfamily transposons as well as resolution sites found
on plasmids (Minakhina et al., 1999). The Tn21-like Tn1403,
Tn6060, Tn6162, and Tn6249, which nest inside the Tn402-like,
carry a class 1 integron possessing the blaVIM−1 gene cassette
(Di Pilato et al., 2015).
In the transposon repository database (Tansirichaiya et al.,
2019), a total of 20 transposons carried the gene encoding
carbapenemases (Supplementary Table 1), and of those, 19
transposons are associated with class 1 integrons harboring the
blaVIM (n = 9), blaIMP (n = 6), blaGES (n = 2), blaSIM (n = 1), and
blaDIM (n = 1) gene cassettes. The 207 complete P. aeruginosa
genomes from the Genome Database included a total of 29
chromosomal class 1 integrons with a carbapenemase-encoding
gene cassette. Among those, 20 integrons included a part or
the entire set of the TniABQR transposition module of the
Tn402-like.
Resistance Islands Harboring the
Carbapenemase-Encoding Genes
Genomic islands carrying many foreign genes are useful for
adaptation by providing multiple fitness-associated elements to
P. aeruginosa in a single event of horizontal gene transfer (Kung
et al., 2010). Genomic islands are often free to move in and out of
the chromosome, and pKLC102, a 100-kb plasmid identified in
P. aeruginosa C strain, is an example of this (Klockgether et al.,
2004). The plasmid pKLC102 was found simultaneously in the
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FIGURE 9 | Transposons giving mobility to integrons. Transposons are indicated in scale with the component. The accession number of each sequence is indicated
in brackets. Arrows indicate open reading frames with filled colors that differ by function: yellow, transposition; orange, class 1 integrase; red, antimicrobial
resistance; green, heavy metal resistance (Radstrom et al., 1994; Minakhina et al., 1999; Shi et al., 2018).
FIGURE 10 | Schematic presentation of the structure of genomic islands belonging to the three groups. The schematic structure is presented for the three groups of
genomic islands: (A) Group 1 resistance islands equipping the tyrosine-based integrase gene at the 5’ terminal and the conjugative transfer machinery gene cluster
at the 3’ terminus, (B) Group 2 resistance islands carrying a transposition module of a whole or a partial TniABQR component, (C) and the others. The genes are
indicated with open arrows and colored based on function: genes for integration and recombination of the genomic island are in yellow, genes for antimicrobial
resistance (AMR) are in red, genes for heavy metal resistance (HMR) are in green, the intI1 gene is in orange, conjugative transfer module mostly composed of the
type 4 pili assembly genes is in black, and the core gene is in gray. The open box indicates inverted repeats (IRs) left and right, named the attL and attR loci for
integration conjugative elements.
chromosome as a genomic island being integrated into the 3′ end
of the tRNALys gene in favor of an att site.
Genomic islands are typically inserted at the 3′ end of a
transfer RNA (tRNA) gene; however, they are also targeted
elsewhere in the chromosome (Klockgether et al., 2011). Genomic
islands are easily differentiated from the core genome by their
atypical G+C contents, differing from the typical P. aeruginosa
G+C content of 65–67% and atypical oligonucleotide usage.
Genomic islands typically harbor the genes for factors involved
in mobility, such as integrases, transposases, ISs, and other
components responsible for biological processes. Genomic
islands are categorized accordingly to their main characteristics
determined by the gene content, such as pathogenicity, symbiosis,
metabolic, fitness, or drug resistance. Thus far, 25 genomic islands
have been identified: two P. aeruginosa pathogenic islands, PAPI-
1 and PAPI-2; 17 P. aeruginosa genomic islands, PAGI-1 to
PAGI-17; five Liverpool epidemic strain genomic islands, LESGI-
1 to LESGI-5; and a plasmid-origin genomic island, pKLC102.
As an effort to group the genomic islands, Kung et al. (2010)
suggested two families of genomic islands by conserved function
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and synteny of the backbone genes, and Klockgether et al. (2011)
proposed that any known genomic islands originated from an
ancestry based on conserved orthologs. However, no scheme is
publicly endorsed.
Genomic islands carrying the antimicrobial resistance genes,
so-called resistance islands, specifically provide a great advantage
for survival to bacterial hosts in clinical settings. Among the 25
genomic islands, only three—PAGI-13 in P. aeruginosa ST277
(Silveira et al., 2014) and PAGI-15 in ST244 and PAGI-16 in
ST235, respectively (Hong et al., 2016)—were resistance islands
carrying antimicrobial resistance determinants, and only two,
PAGI-15 (blaGES−24) and PAGI-16 (blaIMP−6, or blaIMP−10),
harbored a carbapenemase-encoding gene (Table 1; Hong et al.,
2016). One unnamed PAGI-2-like island in P. aeruginosa
ST235 carrying the blaGES−5 gene has also been reported
(Abril et al., 2019).
In addition, the PA143/97 genomic island, which was
manufactured to include the Tn6249 carrying two class 1
integrons harboring the blaVIM−2 gene cassette, was reported
(Martinez et al., 2012; Di Pilato et al., 2015).
Pseudomonas aeruginosa is able to obtain multidrug resistance
at once through resistance islands. Since this review focuses
on carbapenem resistance in P. aeruginosa, the exploration
is restricted to genomic islands harboring carbapenemase-
encoding genes.
Among the 207 complete genomes of P. aeruginosa extracted
from the Genome Database, a total of 38 chromosomes harbor
resistance islands carrying the carbapenemase-encoding gene,
and eight of those carry two resistance islands. In total, 45
resistance islands, sized between 8,858 and 117,103 bp, were
analyzed. The G+C contents varied from 55.5 to 65.5%, which
were lower than those of the chromosomes, which were from 65
to 67%, and the integration sites varied.
The 45 resistance islands carrying the carbapenemase-
encoding gene were classified into three groups by the
transposition module (Table 2). Group 1 resistance islands
furnish the tyrosine-based integrase gene at the 5’ terminal
and the conjugative transfer machinery gene cluster at the 3′
terminus (Figure 10). Group 1 can be further grouped into two
subgroups: group 1a, with a core structure of ICETn4371 mostly
targeting OprD of OccD4/OpdT tyrosine or adenylate cyclase
ExoY, and group 1b, which resembles the known multidrug-
resistant genomic islands PAGI-13, PAGI-15, and PAGI-16
targeting tRNAGly. Resistance islands belonging to group 1a had
G+C contents between 64.5 and 65.1%, and the size was 44–
74 kbp. The blaSPM−1 and blaNDM−1 genes carried by the group
1a resistance islands were all associated with IS91-like ISCRs
composing unit transposons, and neither the other antimicrobial
resistance determinants nor the heavy metal resistance-associated
genes were identified in the resistance island. Meanwhile, the
G+C contents of group 1b ranged between 60.5 and 64.2%, and
the size ranged from 37 to 117 kbp. The upper cluster of group
1b, including four genomic islands (Table 2), targeted tRNAGly
at the locus PA0714 of the genome of P. aeruginosa PAO1
(NCBI RefSeq, NC_002516.2). Characteristically, the genomic
islands belonging to the cluster always possess the mercury
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TABLE 2 | Resistance islands carrying the carbapenemase-encoding gene in Pseudomonas aeruginosa.
aThe molecular phylogenetic trees were constructed using the aligned amino acid sequences of the integration module, either the tyrosine-type integrase/recombinase
or the concatenated TniABQR for transposition, using the maximum likelihood method implemented in the PhyML program (v. 3.0 aLRT) with the WAG matrix and a
gamma correction for variable evolutionary rates (Guindon and Gascuel, 2003). A total of 100 bootstrap experiments are carried out; the red dots at the node indicate
perfect robustness.
b If the chromosome includes two genomic islands, each case is indicated with numbers 1/2 and 2/2 in brackets following the GenBank accession number.
c Integration sites are indicated using the locus tag of the genome of P. aeruginosa PAO1 (NCBI RefSeq, NC_002516.2).
d In0 is indicated with “0.”
eAntimicrobial resistance genes located in a class 1 integron and transposons are indicated, and the genes encoding carbapenemase are in boldface.
and the carbapenemase-encoding genes are carried by class
1 integrons as a gene cassette. The eight genomic islands
belonging to the next cluster of subgroup 1b targeted tRNAGly
either at the locus PA2583 or PA2817 of the PAO1 genome.
A quarter of the genomic islands possess a class 1 integron, and
the acquisition of the carbapenemase-encoding gene is mostly
due to ISCR elements. Pieces of the heavy metal gene cluster
have been observed.
The group 2 resistance islands contain a transposition module
composed of a whole or a partial TniABQR component. The
resistance islands had obviously lower G+C contents, between
55.5 and 62.0%, and the sizes were diverse, from 8.8 to 105 kbp.
The composition of the resistance islands in group 2 corresponds
to that of the Proteus genomic island PGI-1 (Mac Aogain
et al., 2016). The resistance islands are constructed through
the accumulated assemblage on a Tn402 backbone. Such an
assemblage of transposons is commonly observed in the AbaR-
type resistance islands in A. baumannii, which evolved from the
Tn6019 backbone (Krizova et al., 2011).
In the case of the remaining two resistance islands,
categorization is unavailable since only two cases of
possible clonal relations are available from the GenBank
database. Neither a specific tyrosine-based recombinase
nor a transposition component has been identified in
the resistance islands; however, they are flanked by 20-bp
inverted repeats.
CONCLUSION
Carbapenems represent a valuable therapeutic option for patients
with infections caused by multidrug-resistant P. aeruginosa. It
is ironic that carbapenem resistance, especially that conferred
by carbapenemase production, is closely related to multidrug
resistance, highlighting the role of modular mobile units
carrying multiple antimicrobial resistance determinants. The
molecular epidemiology of antimicrobial resistance has been
studied by traditional methodologies based on PCR and Sanger
sequencing to identify the resistance genes and to distinguish the
fundamental mobile genetic elements carrying the gene, i.e., gene
cassettes of integrons, transposons, and plasmids. The present
era of massive next-generation sequencing, mostly the long-read
sequencing, allows resolving a wide range of complex genome
regions, such as modular mobile units associated with genes
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for antimicrobial resistance, also known as resistance islands.
Such an extensive analysis has been carried out for limited
numbers of the P. aeruginosa genome mostly for the genomic
islands unrelated to antimicrobial resistance determinants.
Among the plenty genomic islands in the genome of
P. aeruginosa, resistance islands have a meaning beyond genome
plasticity. Such a modular mobile unit harboring antimicrobial
resistance determinants is able to disseminate by itself and
capture an alien gene for resistance, which means the resistance
islands and high-risk clones are the A to Z of acquisition of
multidrug resistance. Our trial to classify P. aeruginosa resistance
islands needs improvement with more cases for resistance islands.
The global spread of the carbapenem-resistant P. aeruginosa
is one of the major global public health challenges, and the
epidemiological scenario is often associated with the circulation
of carbapenemase-encoding genes linked with (i) the endemic
carbapenemase gene and (ii) the carbapenem usage in clinical
settings. The KPC-producing P. aeruginosa in KPC-endemic
United States, the SPM-producing P. aeruginosa in SPM-
endemic Brazil, and the NDM-producing P. aeruginosa in NDM-
endemic India exemplify well the first linkage. The second
linkage is illustrated through the dominance of IMP-6-producing
P. aeruginosa in South Korea, in which meropenem usage
is approximately twice more in clinical settings than that of
imipenem. Since IMP-6 has greater hydrolyzing activity to
meropenem than to imipenem compared to the other subtypes
of IMP enzymes, producing the IMP-6 subtype is favorable
to the bacterial host. It emphasizes that the carbapenemase-
producing organisms should be controlled regardless of the
bacterial host, and control includes both surveillance study and
antimicrobial stewardship. Needless to say, more attention is
needed to be paid to the emergence and spread of the high-
risk P. aeruginosa clones, together with their enzymatic/non-
enzymatic carbapenem resistance. Though continuing efforts
are being made to develop the beta-lactamase inhibitors in
order to preserve the efficacy of beta-lactam drugs including
carbapenems, it is fruitful just for the serine beta-lactamases.
Development of the inhibitors for MBLs, which are frequently
produced by P. aeruginosa, is eager to be accelerated.
Despite the efforts to control the spread of carbapenem-
resistant P. aeruginosa, a conclusive solution to the issue is still
far from being accomplished. Surveillance study for the drug-
resistant pathogen is essential and global collaboration using
harmonized methods is important for a practical comparison
of the outputs. In addition, to fight against the drug-resistant
pathogen, we need to understand how the pathogens acquire
resistance determinants. Taking the advantages of up-to-date
techniques, assessment of the bacterial genome should be
carried out, not only for the mobile genetic elements carrying
a carbapenemase-encoding gene but also for the genomic
islands. Furthermore, through the technique, the mobile genetic
elements should be investigated extensively, and it would allow a
comprehensive grasp of the dissemination of drug resistance.
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